ANXA1 and intrahepatic cholangiocarcinoma: These findings reinforce the translational potential of ANXA1-targeted therapy and support our current work by providing a promising therapeutic rationale for disrupting the ANXA1 axis in intrahepatic cholangiocarcinoma.